Generation Bio to Present at Jefferies Virtual Gene Therapy/Editing Summit
Generation Bio Co. (Nasdaq: GBIO), a leader in genetic medicines for rare and prevalent diseases, announced that its CEO, Geoff McDonough, will participate in a fireside chat at the Jefferies Virtual Gene Therapy/Editing Summit on October 27 at 5:00 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Generation Bio Co. (Nasdaq: GBIO), a leader in genetic medicines for rare and prevalent diseases, announced that its CEO, Geoff McDonough, will participate in a fireside chat at the Jefferies Virtual Gene Therapy/Editing Summit on October 27 at 5:00 p.m. ET. A live webcast will be available on the company's investor website, with a replay accessible for 30 days after the event. The company focuses on innovative genetic therapies through its proprietary non-viral platform, which aims to provide durable treatments and scalable manufacturing for more patients globally.
Details
News Market Reaction – GBIO
The recorded move for GBIO in the trading session of this news was +2.02%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced today that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Virtual Gene Therapy/Editing Summit on Wednesday, October 27 at 5:00 p.m. ET.
A live webcast of the panel will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.
About Generation Bio
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases. The company’s non-viral genetic medicine platform incorporates a novel DNA construct called closed-ended DNA, or ceDNA; a unique cell-targeted lipid nanoparticle delivery system, or ctLNP; and a highly scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis, or RES, to produce ceDNA. The platform is designed to enable multi-year durability from a single dose, to deliver large genetic payloads, including multiple genes, to specific tissues, and to allow titration and redosing to adjust or extend expression levels in each patient. RES has the potential to expand Generation Bio’s manufacturing scale to hundreds of millions of doses to support its mission to extend the reach of genetic medicine to more people, living with more diseases, around the world.
For more information, please visit www.generationbio.com.
Contact:
Investors
Maren Killackey
Generation Bio
mkillackey@generationbio.com
541-646-2420
Media
Alicia Webb
Generation Bio
awebb@generationbio.com
847-254-4275
Lisa Raffensperger
Ten Bridge Communications
lisa@tenbridgecommunications.com
617-903-8783
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.